{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:51:06Z","timestamp":1787010666664,"version":"build-2736575974"},"posted":{"date-parts":[[2025,11,28]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":28,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,11,28]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  Artemisinin-based combination therapies (ACTs) remain the cornerstone of malaria treatment, yet the emergence of artemisinin partial resistance (ART-R) in Africa threatens their efficacy. ART-R is primarily associated with mutations in the\n                  <jats:italic>Plasmodium falciparum kelch13<\/jats:italic>\n                  (K13) gene, notably R561\n                  <jats:bold>H<\/jats:bold>\n                  , which has been linked to delayed parasite clearance in East Africa. We conducted longitudinal molecular surveillance in Tanzania\u2019s Kagera region from 2021 to 2023 to characterize temporal and spatial trends in ART-R and other antimalarial resistance markers. Using molecular inversion probes targeting key antimalarial resistance genes, we genotyped 2,826 isolates from seven districts. The WHO-validated K13 mutation R561\n                  <jats:bold>H<\/jats:bold>\n                  persisted in border districts of Karagwe and Kyerwa, with prevalence ranging from 14-26%, and appeared for the first time in Muleba (5.0%) and Bukoba rural district (0.7%) in 2023, indicating eastward spread toward Lake Victoria. Regional average prevalence of R561\n                  <jats:bold>H<\/jats:bold>\n                  rose from 5.5% in 2021 to 11.3% in 2022, then stabilized at 6.9% in 2023. Additional validated (A675\n                  <jats:bold>V<\/jats:bold>\n                  ) and candidate (V568\n                  <jats:bold>G<\/jats:bold>\n                  , P441\n                  <jats:bold>L<\/jats:bold>\n                  ) mutations were detected at low frequencies, suggesting ongoing diversification of the parasite population under local selection pressures. Partner-drug resistance markers showed minimal change: MDR1\n                  <jats:bold>N<\/jats:bold>\n                  86Y remained near fixation, while CRT K76\n                  <jats:bold>T<\/jats:bold>\n                  declined from 5.9% (2021) to 2.4% (2023). Antifolate resistance was entrenched, with early DHFR and DHPS mutations near fixation and high-level resistance markers (DHFR I164\n                  <jats:bold>L<\/jats:bold>\n                  and DHPS A581\n                  <jats:bold>G<\/jats:bold>\n                  ) exhibiting marked spatial heterogeneity, peaking at 38.1% and 48.1%, respectively, in eastern districts. These findings reveal micro-geographic heterogeneity in resistance and ongoing spread, emphasizing the need for district-level surveillance to detect emerging hotspots and guide interventions. Sustained molecular monitoring is critical to inform treatment policy, preserve ACT efficacy, and mitigate the risk of widespread resistance in East Africa.\n                <\/jats:p>\n                <jats:p>\n                  Artemisinin-based combination therapies (ACTs) remain the cornerstone of malaria treatment, yet the emergence of artemisinin partial resistance (ART-R) in Africa threatens their efficacy. ART-R is primarily associated with mutations in the\n                  <jats:italic>Plasmodium falciparum<\/jats:italic>\n                  kelch13 (K13) gene, notably R561\n                  <jats:bold>H<\/jats:bold>\n                  , which has been linked to delayed parasite clearance in East Africa. We conducted longitudinal molecular surveillance in Tanzania\u2019s Kagera region from 2021 to 2023 to characterize temporal and spatial trends in ART-R and other antimalarial resistance markers. Using molecular inversion probes targeting key antimalarial resistance genes, we genotyped 2,826 isolates from seven districts. The WHO-validated K13 mutation R561\n                  <jats:bold>H<\/jats:bold>\n                  persisted in border districts of Karagwe and Kyerwa, with prevalence ranging from 14-26%, and appeared for the first time in Muleba (5.0%) and Bukoba rural district (0.7%) in 2023, indicating eastward spread toward Lake Victoria. Regional average prevalence of R561\n                  <jats:bold>H<\/jats:bold>\n                  rose from 5.5% in 2021 to 11.3% in 2022, then stabilized at 6.9% in 2023. Additional validated (A675\n                  <jats:bold>V<\/jats:bold>\n                  ) and candidate (V568\n                  <jats:bold>G<\/jats:bold>\n                  , P441\n                  <jats:bold>L<\/jats:bold>\n                  ) mutations were detected at low frequencies, suggesting ongoing diversification of the parasite population under local selection pressures. Partner-drug resistance markers showed minimal change: MDR1\n                  <jats:bold>N<\/jats:bold>\n                  86Y remained near fixation, while CRT K76\n                  <jats:bold>T<\/jats:bold>\n                  declined from 5.9% (2021) to 2.4% (2023). Antifolate resistance was entrenched, with early DHFR and DHPS mutations near fixation and high-level resistance markers (DHFR I164\n                  <jats:bold>L<\/jats:bold>\n                  and DHPS A581\n                  <jats:bold>G<\/jats:bold>\n                  ) exhibiting marked spatial heterogeneity, peaking at 38.1% and 48.1%, respectively, in eastern districts. These findings reveal micro-geographic heterogeneity in resistance and ongoing spread, emphasizing the need for district-level surveillance to detect emerging hotspots and guide interventions. Sustained molecular monitoring is critical to inform treatment policy, preserve ACT efficacy, and mitigate the risk of widespread resistance in East Africa.\n                <\/jats:p>","DOI":"10.1101\/2025.11.26.25341086","type":"posted-content","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T23:35:13Z","timestamp":1764372913000},"source":"Crossref","is-referenced-by-count":2,"title":["Temporal Trends in Artemisinin Partial Resistance and Other Antimalarial Drug Mutations in\n                  <i>Plasmodium falciparum<\/i>\n                  from Kagera Region, Northwestern Tanzania, 2021\u20132023"],"prefix":"10.64898","author":[{"given":"Alfred","family":"Simkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salehe","family":"Mandai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abebe A","family":"Fola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeva Wernsman","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dativa","family":"Pereus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bakari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid A","family":"Madebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misago D","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rule B","family":"Mrengela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina J","family":"Kisambale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gervas A","family":"Chacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine I","family":"Mandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filbert","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mbwambo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa","family":"Garimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Chacky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijenunu","family":"Aaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Lusasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Molteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritha J A","family":"Njau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Kajange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samwel L","family":"Nhiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ally","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J","family":"Juliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deus S","family":"Ishengoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025120101001484000_2025.11.26.25341086v1.1","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1016\/S1473-3099(24)00427-4","article-title":"Alarming Plasmodium falciparum resistance to artemisinin-based combination therapy in Africa: the critical role of the partner drug","volume":"24","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025120101001484000_2025.11.26.25341086v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211803)"},{"key":"2025120101001484000_2025.11.26.25341086v1.3","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.24-0870"},{"key":"2025120101001484000_2025.11.26.25341086v1.4","doi-asserted-by":"publisher","DOI":"10.1101\/2025.01.09.25320247"},{"key":"2025120101001484000_2025.11.26.25341086v1.5","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41564-023-01461-4","article-title":"Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in Ethiopia","volume":"8","year":"2023","journal-title":"Nat Microbiol"},{"key":"2025120101001484000_2025.11.26.25341086v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(02)90349-4"},{"key":"2025120101001484000_2025.11.26.25341086v1.7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00875-06"},{"key":"2025120101001484000_2025.11.26.25341086v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00362-1"},{"key":"2025120101001484000_2025.11.26.25341086v1.9","doi-asserted-by":"crossref","first-page":"100920","DOI":"10.1016\/S2666-5247(24)00160-5","article-title":"Prevalence of mutations associated with artemisinin partial resistance and sulfadoxine-pyrimethamine resistance in 13 regions in Tanzania in 2021: a cross-sectional survey","volume":"5","year":"2024","journal-title":"Lancet Microbe"},{"key":"2025120101001484000_2025.11.26.25341086v1.10","doi-asserted-by":"crossref","unstructured":"Kirby, R. , Giesbrecht, D. , Karema, C. , Watson, O. , Lewis, S. , Munyaneza, T. , et al. (2023). Examining the Early Distribution of the Artemisinin-Resistant R561H Mutation in Areas of Higher Transmission in Rwanda. Open Forum Infect Dis 10, ofad149.","DOI":"10.1093\/ofid\/ofad149"},{"key":"2025120101001484000_2025.11.26.25341086v1.11","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis747"},{"key":"2025120101001484000_2025.11.26.25341086v1.12","doi-asserted-by":"publisher","DOI":"10.1101\/2025.01.02.24319706"},{"key":"2025120101001484000_2025.11.26.25341086v1.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210956"},{"key":"2025120101001484000_2025.11.26.25341086v1.14","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1038\/s41467-025-58326-z","article-title":"Impact of dhps mutations on sulfadoxine-pyrimethamine protective efficacy and implications for malaria chemoprevention","volume":"16","year":"2025","journal-title":"Nat Commun"},{"key":"2025120101001484000_2025.11.26.25341086v1.15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12936-021-03584-7","article-title":"Relationships between test positivity rate, total laboratory confirmed cases of malaria, and malaria incidence in high burden settings of Uganda: an ecological analysis","volume":"20","year":"2021","journal-title":"Malar J"},{"key":"2025120101001484000_2025.11.26.25341086v1.16","doi-asserted-by":"publisher","DOI":"10.1101\/2024.12.31.24319821"},{"key":"2025120101001484000_2025.11.26.25341086v1.17","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taaf013"},{"key":"2025120101001484000_2025.11.26.25341086v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)06217-4"},{"key":"2025120101001484000_2025.11.26.25341086v1.19","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae609"},{"key":"2025120101001484000_2025.11.26.25341086v1.20","doi-asserted-by":"publisher","DOI":"10.1101\/2024.07.17.24310448"},{"key":"2025120101001484000_2025.11.26.25341086v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00141-5"},{"key":"2025120101001484000_2025.11.26.25341086v1.22","doi-asserted-by":"publisher","DOI":"10.1086\/427997"},{"key":"2025120101001484000_2025.11.26.25341086v1.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1005-2"},{"key":"2025120101001484000_2025.11.26.25341086v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00142-0"},{"key":"2025120101001484000_2025.11.26.25341086v1.25","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30732-1"},{"key":"2025120101001484000_2025.11.26.25341086v1.26","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad724"},{"key":"2025120101001484000_2025.11.26.25341086v1.27","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.14-0031"},{"key":"2025120101001484000_2025.11.26.25341086v1.28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/infdis\/jiae475","article-title":"High Frequency of Artemisinin Partial Resistance Mutations in the Great Lakes Region Revealed Through Rapid Pooled Deep Sequencing","volume":"231","year":"2025","journal-title":"J Infect Dis"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.11.26.25341086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:52:16Z","timestamp":1768510336000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.11.26.25341086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":28,"URL":"https:\/\/doi.org\/10.1101\/2025.11.26.25341086","relation":{},"subject":[],"published":{"date-parts":[[2025,11,28]]},"subtype":"preprint"}}